Alnylam Pharmaceuticals Inc. (ALNY) Social Stream



Alnylam Pharmaceuticals Inc. (ALNY): $144.41

0.75 (-0.52%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ALNY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#33 of 362

in industry

Featured Post From StockTwits About ALNY

$ALNY New Press Release:

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function. Lumasiran is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being investigated for the treatment of adult and pediatric p (...)

https://wchr.one/96620
WebChronicleToday, published July 29, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!